GSK Plc's U.S.-listed shares surged Wednesday after the pharmaceutical firm boosted its long-term outlook and launched a $2.5 billion stock buyback on the back of optimism about sales of its new drugs ...

The Danish pharmaceutical company expects demand for obesity and diabetes drugs to rise, but forecasts sales growth to slow down this year. Read more.

Q4 2024Management ViewCEO Dame Emma Walmsley highlighted that GSK achieved 8% sales growth in 2024, reaching over ...

CetraRuddy, a New York office, was behind the largest office-to-residential conversion project in New York City to date. 25 ...

Mike Ralston, CEO of Blencowe Resources (BRES) and Manuel Pablo Zúñiga-Pflücker, President and CEO of PetroTal (PTAL) will be presenting and taking live Q&A at focusIR's Investor Webinar on Tuesday ...

European markets opened mixed on Wednesday, with investors looking ahead to more earnings from a number of key companies.

GSK and the University of Oxford have joined hands to focus on the potential of cancer prevention through vaccination. The ...

It’s time for a new era of public health—where vaccines are seen as both a scientific triumph and a shared commitment to well-being of all.

The new collaboration between GSK and the Univeristy of Oxford aims to explore cancer prevention through vaccination.

“By exploring pre-cancer biology and building on GSK’s expertise in the science of the immune system ... Medicine to drive ...

(Alliance News) - Pharmaceutical firm GSK PLC and the University of Oxford are creating a new cancer vaccine to prevent the disease from developing. The partnership intends to create a vaccine or ...

GSK’s share price has been pressured recently from several negative events, but this may leave a bargain to be had. I've ...